Gender-related differences in the pharmacokinetics of tolmetin in the rat

G. C. Vidal-Cantú, V. Granados-Soto, F. J. Flores-Murrieta

Research output: Contribution to journalArticle

Abstract

Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) that is used in the treatment of arthritis and osteoarthritis. Its mechanism of action, as other NSAIDs, is by inhibition of prostaglandin synthesis. Despite the fact of gender-related differences in the pharmacokinetics (PK) and pharmacodynamics (PD) of some NSAIDs, tolmetin PK have only been evaluated in males at present. We therefore compared tolmetin PK in male and female rats. Animals received an oral 10 mg/kg tolmetin dose under fasting conditions and blood samples were drawn at different times over a 4 h period. Tolmetin concentration in whole blood was determined by HPLC. Tolmetin blood levels increased rapidly reaching a peak of 13.5 ±3.1 μg/ml in 0.22 ± 0.09 h in males and 13.4 ±2.1 μg/ml in 0.33 ±0.09 h in females. Tolmetin was eliminated more rapidly in males with a half-life of 0.9 ±0.09 h, compared to a value of 3.3 ±0.54 h in females. As a result, drug bioavailability was higher in females, AUC values being 15.4 ±2.74 and 28.2 ±4.35 μg/h/ml. Our results confirm PK differences among genders for NSAIDs in experimental animals. Further investigation is required to establish the clinical impact of such differences in humans.
Original languageAmerican English
Pages (from-to)288
Number of pages1
JournalProceedings of the Western Pharmacology Society
StatePublished - 1 Dec 1998
Externally publishedYes

Fingerprint

Tolmetin
Pharmacokinetics
Non-Steroidal Anti-Inflammatory Agents
Osteoarthritis
Pharmaceutical Preparations
Biological Availability
Area Under Curve
Arthritis
Prostaglandins
Half-Life
Fasting
Anti-Inflammatory Agents
High Pressure Liquid Chromatography

Cite this

@article{f7a82887aa9a41a0848d7ed66a8532c1,
title = "Gender-related differences in the pharmacokinetics of tolmetin in the rat",
abstract = "Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) that is used in the treatment of arthritis and osteoarthritis. Its mechanism of action, as other NSAIDs, is by inhibition of prostaglandin synthesis. Despite the fact of gender-related differences in the pharmacokinetics (PK) and pharmacodynamics (PD) of some NSAIDs, tolmetin PK have only been evaluated in males at present. We therefore compared tolmetin PK in male and female rats. Animals received an oral 10 mg/kg tolmetin dose under fasting conditions and blood samples were drawn at different times over a 4 h period. Tolmetin concentration in whole blood was determined by HPLC. Tolmetin blood levels increased rapidly reaching a peak of 13.5 ±3.1 μg/ml in 0.22 ± 0.09 h in males and 13.4 ±2.1 μg/ml in 0.33 ±0.09 h in females. Tolmetin was eliminated more rapidly in males with a half-life of 0.9 ±0.09 h, compared to a value of 3.3 ±0.54 h in females. As a result, drug bioavailability was higher in females, AUC values being 15.4 ±2.74 and 28.2 ±4.35 μg/h/ml. Our results confirm PK differences among genders for NSAIDs in experimental animals. Further investigation is required to establish the clinical impact of such differences in humans.",
author = "Vidal-Cant{\'u}, {G. C.} and V. Granados-Soto and Flores-Murrieta, {F. J.}",
year = "1998",
month = "12",
day = "1",
language = "American English",
pages = "288",
journal = "Proceedings of the Western Pharmacology Society",
issn = "0083-8969",
publisher = "Western Pharmacology Society",

}

Gender-related differences in the pharmacokinetics of tolmetin in the rat. / Vidal-Cantú, G. C.; Granados-Soto, V.; Flores-Murrieta, F. J.

In: Proceedings of the Western Pharmacology Society, 01.12.1998, p. 288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gender-related differences in the pharmacokinetics of tolmetin in the rat

AU - Vidal-Cantú, G. C.

AU - Granados-Soto, V.

AU - Flores-Murrieta, F. J.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) that is used in the treatment of arthritis and osteoarthritis. Its mechanism of action, as other NSAIDs, is by inhibition of prostaglandin synthesis. Despite the fact of gender-related differences in the pharmacokinetics (PK) and pharmacodynamics (PD) of some NSAIDs, tolmetin PK have only been evaluated in males at present. We therefore compared tolmetin PK in male and female rats. Animals received an oral 10 mg/kg tolmetin dose under fasting conditions and blood samples were drawn at different times over a 4 h period. Tolmetin concentration in whole blood was determined by HPLC. Tolmetin blood levels increased rapidly reaching a peak of 13.5 ±3.1 μg/ml in 0.22 ± 0.09 h in males and 13.4 ±2.1 μg/ml in 0.33 ±0.09 h in females. Tolmetin was eliminated more rapidly in males with a half-life of 0.9 ±0.09 h, compared to a value of 3.3 ±0.54 h in females. As a result, drug bioavailability was higher in females, AUC values being 15.4 ±2.74 and 28.2 ±4.35 μg/h/ml. Our results confirm PK differences among genders for NSAIDs in experimental animals. Further investigation is required to establish the clinical impact of such differences in humans.

AB - Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) that is used in the treatment of arthritis and osteoarthritis. Its mechanism of action, as other NSAIDs, is by inhibition of prostaglandin synthesis. Despite the fact of gender-related differences in the pharmacokinetics (PK) and pharmacodynamics (PD) of some NSAIDs, tolmetin PK have only been evaluated in males at present. We therefore compared tolmetin PK in male and female rats. Animals received an oral 10 mg/kg tolmetin dose under fasting conditions and blood samples were drawn at different times over a 4 h period. Tolmetin concentration in whole blood was determined by HPLC. Tolmetin blood levels increased rapidly reaching a peak of 13.5 ±3.1 μg/ml in 0.22 ± 0.09 h in males and 13.4 ±2.1 μg/ml in 0.33 ±0.09 h in females. Tolmetin was eliminated more rapidly in males with a half-life of 0.9 ±0.09 h, compared to a value of 3.3 ±0.54 h in females. As a result, drug bioavailability was higher in females, AUC values being 15.4 ±2.74 and 28.2 ±4.35 μg/h/ml. Our results confirm PK differences among genders for NSAIDs in experimental animals. Further investigation is required to establish the clinical impact of such differences in humans.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33748131748&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=33748131748&origin=inward

M3 - Article

SP - 288

JO - Proceedings of the Western Pharmacology Society

JF - Proceedings of the Western Pharmacology Society

SN - 0083-8969

ER -